Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.

Pharmacogenomics - 1 Jan 2015

Kummer Dominic, Froehlich Tanja K, Joerger Markus, Aebi Stefan, Sistonen Johanna, Amstutz Ursula, Largiadèr Carlo R

Abstract excerpt

AIMS: To assess the association of DPYS and UPB1 genetic variation, encoding the catabolic enzymes downstream of dihydropyrimidine dehydrogenase, with early-onset toxicity from fluoropyrimidine-based chemotherapy. PATIENTS & METHODS: The coding and exon-flanking regions of both genes were sequenced in a discovery subset (164 patients). Candidate variants were genotyped in the full cohort of 514 patients. RESULTS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Young Adult
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amidohydrolases

Share to Antimetabolites, Antineoplastic

Share to Drug-Related Side Effects and Adverse Reactions

Share to Fluorouracil

Share to Pyrimidines

Source

Identifiers

PMID: 26244261
DOI: 10.2217/pgs.15.81

Genes

DPYS
UPB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.PMID 26244261Read ↗

Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.Semantic proximity Read ↗

Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.Semantic proximity Read ↗

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol.Semantic proximity Read ↗

Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.Semantic proximity Read ↗

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Semantic proximity Read ↗

Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.Semantic proximity Read ↗

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping AssaysSemantic proximity Read ↗

Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity.Semantic proximity Read ↗

New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.Semantic proximity Read ↗

In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-UreidopropionaseSemantic proximity Read ↗

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.